//
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study
Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Heart Failure With Preserved Ejection Fraction in the Young